Brennan Katherine sold $225K of MRSH

Brennan Katherine (SVP and General Counsel) sold 1,197 shares of MARSH & MCLENNAN COMPANIES, INC. (MRSH) at $187.90 ($0.22M total) on 2026-09-02.

Original reporting
SEC EDGAR · Brennan Katherine
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$MRSH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

Impact Analysis

02

Market read

Routine insider sale with limited market relevance.

03

What to watch

No material impact on share price expected given the small size.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑02

Background

SEC Form 4 filing discloses a 1,197‑share sale by SVP/General Counsel.

Market effects

none

none

none

Counterpoint

The sale may be routine and not indicative of insider concern.

Key entities

  • Marsh & McLennan Companies, Inc.

    Issuer of the Form 4.

  • Brennan Katherine

    SVP and General Counsel who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRSHMedAI 8/10

Why Marsh (MRSH) Stock Is Trading Up Today

Marsh (MRSH) shares rose 4.7% after reporting Q3 2026 results with 8% revenue growth and 10% increase in adjusted EPS. GAAP earnings were $1.69, adjusted earnings $2.03. The company repurchased $500M in stock and raised its savings target to $600M. Shares closed at $186.43, up 4.5%.

$MRSHHighAI 8/10

Marsh McLennan earnings analysis: questions answered and next catalysts

Marsh McLennan (MRSH) reported Q3 FY2026 earnings on Oct 15, 2026, beating estimates with EPS of $2.03 and revenue of $6.86B. The stock rose 5.49% to $188.19. Analysts had lowered price targets before the report, contributing to the rally. Key questions remain about organic growth durability and valuation. Next catalysts include Q4 earnings, 2027 guidance, and analyst revisions.

$MRSHHighAI 8/10

Marsh McLennan (MRSH) Q3 2026 Earnings Call Transcript

Marsh McLennan (MRSH) reported Q3 2026 earnings with revenue up 8%, adjusted operating income up 6%, and adjusted EPS up 10%. The company highlighted growth in consulting and risk services, increased Thrive savings target to $600M, and progress in AI integration. They also repurchased $500M in stock. Market conditions showed mixed rate changes across regions and lines of business.